You are here: Home: PCU 1 | 2007: Audio Program Guide: PCU 1 | 2007 Audio
 
  Go to interview with Eric A Klein, MD
Go to interview with Anthony V D’Amico, MD, PhD
Go to interview with Nicholas J Vogelzang, MD
 
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Klein, MD Eric A Klein, MD
Professor of Surgery
Cleveland Clinic Lerner College of Medicine
Head, Section of Urologic Oncology
Glickman Urological Institute
Cleveland, Ohio		  
  Click here to download the entire segment  
Track 1 PSA screening, pathologic stage migration and curability of prostate cancer
Track 2 Overall survival with treatment modalities for localized prostate cancer
Track 3 Potential advantages of radical prostatectomy for localized prostate cancer
Track 4 Risk of radiation-induced bowel or bladder cancer and prostatorectal fistulas
Track 5 Potential advantages of robotic and laparoscopic surgery
Track 6 Relationship between surgeon experience and rate of cure of prostate cancer

Track 7 Evolving clinical role of cryosurgery
Track 8 Opportunities for improvement in age-adjusted prostate cancer mortality
Track 9 Chemotherapy in metastatic and hormone-refractory prostate cancer
Track 10 Tolerability of and symptomatic relief with docetaxel in metastatic disease
Track 11 Treatment of PSA-only progression postprostatectomy
audio
Track 12 Oral platinum satraplatin for hormone-refractory prostate cancer
audio
Track 13 Survival associated with treatment versus watchful waiting
audio
Track 14 Use of finasteride to enhance PSA screening
audio
Track 15 Development of a clinical assay for prediction of recurrence risk of localized prostate cancer
audio
Track 16 Epidemiologic evidence for prostate cancer as an infectious disease
audio
Track 17 Single nucleotide polymorphism in HPC1, RNase L protein and viral susceptibility
audio
Track 18 XMRV virus as a potential etiology for a subset of prostate cancer
audio
Track 19 Update of SELECT: Selenium, vitamin E or the combination in the prevention of prostate cancer
audio
Track 20 Inferior outcomes in African-American patients following localized therapy for prostate cancer
audio
Track 21 Chromosomal translocations and gene fusion events and the development of aggressive prostate cancer
audio
Track 22 Mechanism of androgen resistance in prostate cancer
     
D'Amico, MD Anthony V D’Amico, MD, PhD
Professor and Chief of Genitourinary Radiation Oncology
Brigham and Women’s Hospital
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts		  
  Click here to download the entire segment  
Track 1 Recent developments in the management of high-risk localized prostate cancer
Track 2 Hormonal therapy and risk of cardiovascular morbidity
Track 3 Duration of hormonal therapy and cardiovascular events
Track 4 Relationship between duration of testosterone suppression and clinical outcomes of men with high-risk localized disease
Track 5 Duration of testosterone suppression and patient age
Track 6 Use of bicalutamide monotherapy

Track 7 Hormonal therapy for intermediate- or high-risk prostate cancer
Track 8 Treatment approach based on postprostatectomy PSA doubling time
Track 9 Fraction of patients presenting with intermediate- or high-risk disease
Track 10 Use and duration of maximal androgen blockade
Track 11 Effect of finasteride for hair loss on interpretation of PSA screening results
audio
Track 12 Dose-escalated radiation therapy and hormonal therapy for high-risk disease
audio
Track 13 Tolerability of docetaxel
audio
Track 14 Increase in a multimodality approach in the care of patients with prostate cancer
audio
Track 15 Future research directions in prostate cancer
audio
Track 16 Clinical trials of systemic therapy in combination with docetaxel for intermediateand high-risk prostate cancer
audio
     
VogelZang, MD Nicholas J Vogelzang, MD
Director, Nevada Cancer Institute Las Vegas
Professor of Medicine
University of Nevada School of Medicine
Las Vegas, Nevada		  
  Click here to download the entire segment  
Track 1 SWOG-9346: Intermittent versus continuous combined androgen blockade with bicalutamide and goserelin in patients with metastatic prostate cancer
Track 2 Quality of life in men receiving continuous versus intermittent therapy
Track 3 Clinical presentation of newly diagnosed metastatic disease
Track 4 Combined androgen blockade with bicalutamide
Track 5 Clinical investigations of vaccines for the treatment of advanced prostate cancer
arrow
Track 6 Clinical trials evaluating docetaxel in advanced prostate cancer
arrow
Track 7 Use of docetaxel in patients with hormone-refractory PSA-only progression
arrow
Track 8 Risks and benefits of docetaxel in the treatment of metastatic disease
arrow
Track 9 Referral of patients with prostate cancer to medical oncologists for consideration of treatment with chemotherapy
arrow
Track 10 Clinical trials of adjuvant chemotherapy in early prostate cancer
arrow
Track 11 EPC trials of bicalutamide as adjuvant monotherapy
arrow
Track 12 Integration of medical oncologists into the care of patients with prostate cancer
arrow